14-3-3 beta exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma

Glioma is a type of tumor that affects the central nervous system. It has been demonstrated that 14-3-3 beta, a protein that is mainly concentrated in the brain, serves an important role in tumor regulation. However, the mechanism of action of 14-3-3 beta that underlies the pathogenesis of glioma remains to be elucidated. In the present study, 14-3-3 beta was silenced by RNA interference in the human glioma cell line U373-MG. Following knockdown of 14-3-3 beta, the proliferation, colony formation, cell cycle progression, migration and invasion of U373-MG cells were significantly decreased (P<0.01), whereas cell apoptosis was increased (P<0.01). Furthermore, in a tumor xenograft experiment, silencing 14-3-3 beta significantly inhibited the in vivo tumor growth of U373-MG cells (P<0.01). The results demonstrated that 14-3-3 beta levels were significantly higher in human glioma tissues compared with normal brain tissues (P<0.01) and high 14-3-3 beta expression was significantly associated with advanced pathological grade (P<0.03) and low Karnofsky performance scale (P<0.003). Patients with glioma who had high 14-3-3 beta levels had a significantly shorter survival time compared with those with low expression of 14-3-3 beta (P=0.031), suggesting that 14-3-3 beta may be an effective predictor of the prognosis of patients with glioma. The results of the present study indicate that 14-3-3 beta serves an oncogenic role in glioma, suggesting that 14-3-3 beta may have potential as a promising therapeutic target for glioma.